StageZero Life Sciences (OTCMKTS:SZLSF – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Institutional and Insider Ownership
5.4% of Navidea Biopharmaceuticals shares are owned by institutional investors. 32.4% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares StageZero Life Sciences and Navidea Biopharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|StageZero Life Sciences||$5.07 million||1.56||-$7.48 million||($0.10)||-0.79|
|Navidea Biopharmaceuticals||$530,000.00||57.74||-$11.73 million||($0.40)||-2.53|
StageZero Life Sciences has higher revenue and earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than StageZero Life Sciences, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and price targets for StageZero Life Sciences and Navidea Biopharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|StageZero Life Sciences||0||0||0||0||N/A|
Volatility and Risk
StageZero Life Sciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.
This table compares StageZero Life Sciences and Navidea Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|StageZero Life Sciences||-147.77%||N/A||-169.49%|
StageZero Life Sciences beats Navidea Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.
About StageZero Life Sciences (Get Rating)
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.
About Navidea Biopharmaceuticals (Get Rating)
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.